Spots Global Cancer Trial Database for neoadjuvant treatment
Every month we try and update this database with for neoadjuvant treatment cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Treatment for Advanced Rectal Carcinoma | NCT02551237 | Rectal Carcinom... | 50 Gy Capecitabine 25 Gy | 75 Years - | UNICANCER | |
| Breast Cancer Registry Platform | NCT03417115 | Breast Cancer | 18 Years - | iOMEDICO AG | ||
| Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma | NCT04197882 | Melanoma | OrienX010 Combi... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT) | NCT00462995 | Non Small Cell ... | Erlotinib Erlotinib | 18 Years - 95 Years | University Health Network, Toronto | |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | NCT04730219 | Muscle Invasive... Urothelial Carc... | Tislelizumab Nab paclitaxel | 18 Years - | Tianjin Medical University Second Hospital | |
| Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer | NCT05524012 | Locally Advance... Neoadjuvant Tre... Radiotherapy Adaptive Treatm... | Blood sample MRI scan | 18 Years - | Jena University Hospital | |
| Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer | NCT01061359 | Breast Neoplasm | Epirubicin: Obs... | - | Pfizer | |
| Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer | NCT01389440 | Pancreatic Aden... | Gemcitabine and... | 18 Years - 75 Years | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer | NCT02064608 | Prostate Cancer | AZD2014 | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | NCT02272699 | Esophageal Squa... | Nimotuzumab Paclitaxel Cisplatin Radiation Surgery | 18 Years - 65 Years | Peking University | |
| Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer | NCT03199144 | Pancreatic Neop... | Chemotherapy Stereotactic ra... Surgery | 18 Years - | Centre Francois Baclesse, Luxembourg | |
| Ultrasound Imaging, Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment. | NCT00437879 | Breast Cancer I... | - | Sunnybrook Health Sciences Centre | ||
| Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer | NCT01442974 | Pancreatic Canc... | Gemcitabine plu... | 18 Years - | Grupo Hospital de Madrid | |
| Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | NCT02272699 | Esophageal Squa... | Nimotuzumab Paclitaxel Cisplatin Radiation Surgery | 18 Years - 65 Years | Peking University | |
| SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer | NCT05576480 | Rectal Cancer Locally Advance... | Short-course ra... Penpulimab CAPEOX TME surgery | 18 Years - 75 Years | Ruijin Hospital | |
| Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer | NCT05170581 | Non-small Cell ... | Sintilimab Comb... | 18 Years - 75 Years | The Second Affiliated Hospital of Shandong First Medical University | |
| Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC | NCT06002789 | Multiple Cancer Colorectal Canc... | MSI-H/MSS (dMMR... All-MSI-H (dMMR... | 18 Years - 80 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| miRNA and Relevant Biomarkers of BC Patients Undergoing Neoadjuvant Treatment | NCT03779022 | Breast Cancer | microRNA | 18 Years - 75 Years | Peking University First Hospital | |
| PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study) | NCT06345599 | Pancreatic Duct... | Radiotherapy Immunotherapy:G... Chemotherapy:Al... | 18 Years - 75 Years | Second Affiliated Hospital of Soochow University | |
| Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04669496 | Intrahepatic Ch... PD1 Antibody Lenvatinib Gemox Chemother... | Neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma | NCT03601689 | Rectal Neoplasm... | rectal resectio... | 18 Years - | Moroccan Society of Surgery | |
| Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | NCT04177797 | Esophageal Squa... | Toripalimab | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer | NCT06038539 | HR Negative HER... | PERT-IJS plus t... Perjeta plus tr... | 18 Years - 99 Years | Biocon Limited | |
| Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | NCT05751629 | Ovarian Neoplas... | Dostarlimab Bevacizumab Niraparib | 18 Years - | Tesaro, Inc. | |
| Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer | NCT01389440 | Pancreatic Aden... | Gemcitabine and... | 18 Years - 75 Years | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer | NCT02910843 | Rectal Cancer | Regorafenib Capecitabine Radiotherapy Surgery | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer | NCT04515004 | Early Stage Lun... | leucoselect phy... | 21 Years - | VA Office of Research and Development | |
| Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment | NCT02017496 | Breast Cancer | 18 Years - | Oslo University Hospital | ||
| DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors | NCT05684276 | NSCLC Pancoast Tumor | Carboplatin Paclitaxel Nivolumab | 18 Years - 75 Years | Fundación GECP | |
| Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation. | NCT01217619 | Non Small Cell ... | erlotinib | 18 Years - | Shanghai Chest Hospital | |
| Long Term Use of SAVI SCOUT: Pilot Study | NCT03015649 | Breast Diseases | SAVI SCOUT Surg... | 18 Years - 90 Years | Envision Healthcare Scientific Intelligence, Inc. | |
| Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | NCT04620473 | Neoadjuvant Tre... Rectal Cancer Anlotinib | Anlotinib+Capeo... Capeox | 18 Years - 75 Years | Shanghai Minimally Invasive Surgery Center | |
| Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC | NCT06002789 | Multiple Cancer Colorectal Canc... | MSI-H/MSS (dMMR... All-MSI-H (dMMR... | 18 Years - 80 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | NCT02489006 | Ovarian Cancer Fallopian Tube ... Neoadjuvant Tre... Debulking Surgi... | Olaparib Platinum-based ... | 18 Years - | University Health Network, Toronto | |
| Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | NCT05751629 | Ovarian Neoplas... | Dostarlimab Bevacizumab Niraparib | 18 Years - | Tesaro, Inc. | |
| FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole | NCT00199134 | Breast Cancer | Letrozole | - | Jules Bordet Institute | |
| Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer | NCT06038539 | HR Negative HER... | PERT-IJS plus t... Perjeta plus tr... | 18 Years - 99 Years | Biocon Limited | |
| Resistance vs. Aerobic Training on Breast Cancer Patients Undergoing Neoadjuvant Treatment | NCT05297773 | Breast Cancer | Aerobic Trainin... Resistance Trai... Control group | 18 Years - | Fundacao Champalimaud | |
| Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer | NCT05170581 | Non-small Cell ... | Sintilimab Comb... | 18 Years - 75 Years | The Second Affiliated Hospital of Shandong First Medical University | |
| Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC | NCT05189730 | Esophageal Squa... | Tirelizumab Paclitaxel Carboplatin Neoadiuvant rad... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Long Term Use of SAVI SCOUT: Pilot Study | NCT03015649 | Breast Diseases | SAVI SCOUT Surg... | 18 Years - 90 Years | Envision Healthcare Scientific Intelligence, Inc. | |
| Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment | NCT02017496 | Breast Cancer | 18 Years - | Oslo University Hospital | ||
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study | NCT05328336 | Muscle Invasive... | Tislelizumab Na... | 18 Years - | Tianjin Medical University Second Hospital | |
| PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers | NCT00535418 | Breast Cancer | Letrozole | 18 Years - | Novartis | |
| Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas | NCT04268121 | Neuroendocrine ... Digestive Cance... | Neoadjuvant tre... Adjuvant treatm... | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | NCT04512430 | Non Small Cell ... EGFR Gene Mutat... | Atezolizumab Bevacizumab Carboplatin Pemetrexed | 18 Years - | Fundación GECP | |
| Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer | NCT04515004 | Early Stage Lun... | leucoselect phy... | 21 Years - | VA Office of Research and Development | |
| MRI Features in Neoadjuvant Treatment Decisions for Patients With Rectal Cancer | NCT05609149 | Rectal Cancer | total mesorecta... | 18 Years - 80 Years | Sun Yat-sen University | |
| Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | NCT01077154 | Breast Cancer | Placebo Denosumab | 18 Years - | Amgen | |
| Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | NCT03879577 | Breast Cancer Breast Cancer F... HER2-positive B... Breast Cancer S... Breast Cancer S... | Docetaxel Herceptin FEC Tamoxifen Letrozole LHRH agonist | 18 Years - 70 Years | University of Chicago | |
| Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy | NCT04923620 | Neoadjuvant Tre... Rectal Cancer Cetuximab Radiotherapy | cetuximab+mFOLF... short-course ra... | 18 Years - 75 Years | Shanghai Minimally Invasive Surgery Center | |
| Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC | NCT05189730 | Esophageal Squa... | Tirelizumab Paclitaxel Carboplatin Neoadiuvant rad... | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | NCT04615143 | Recurrent Hepat... | Tislelizumab Tislelizumab co... | 18 Years - 75 Years | Sun Yat-sen University | |
| Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer | NCT01442974 | Pancreatic Canc... | Gemcitabine plu... | 18 Years - | Grupo Hospital de Madrid | |
| Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma | NCT03601689 | Rectal Neoplasm... | rectal resectio... | 18 Years - | Moroccan Society of Surgery | |
| A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer | NCT03574779 | Ovarian Neoplas... | Niraparib TSR-042 Bevacizumab Carboplatin Paclitaxel | 18 Years - | Tesaro, Inc. | |
| Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | NCT01937117 | Breast Cancer | Positron emissi... Trastuzumab Pertuzumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Neoadjuvant Treatment of Colon Cancer | NCT01108107 | Colon Cancer | Oxaliplatin Capecitabine Oxaliplatin Capecitabine Panitumumab | 18 Years - | Vejle Hospital | |
| Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) | NCT02676349 | Pancreatic Carc... | mFolfirinox Chemoradiothera... surgery Adjuvant chemot... | 18 Years - 75 Years | Institut de Cancérologie de Lorraine | |
| Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity. | NCT05946460 | Lung Cancer | Aumolertinib | 18 Years - 75 Years | The First Affiliated Hospital of Guangzhou Medical University | |
| Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer | NCT05673772 | Rectal Cancer | short-course ra... mFOLFOX6 Chemoradiothera... TME surgery | 20 Years - 75 Years | Kyungpook National University Hospital | |
| Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer | NCT03199144 | Pancreatic Neop... | Chemotherapy Stereotactic ra... Surgery | 18 Years - | Centre Francois Baclesse, Luxembourg | |
| MicroRNA Profiles in Triple Negative Breast Cancer | NCT04771871 | Triple Negative... | Epirubicin Cyclophosphamid... Paclitaxel Carboplatin | 18 Years - 70 Years | University College Hospital, Ibadan | |
| Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer | NCT02059876 | Breast Cancer | carboplatin and... | 18 Years - | Guangdong Provincial People's Hospital | |
| Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients | NCT04983121 | Breast Neoplasm... | Next-generation... | 18 Years - 75 Years | Shengjing Hospital | |
| Multicentric Retrospective Review of Extracapsular Lymph Node Involvement After Esophagectomy | NCT01837173 | Cancer | 18 Years - | University Hospital, Gasthuisberg | ||
| Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer | NCT00506844 | Rectal Neoplasm... Neoadjuvant Tre... | Cetuximab, Irin... | 18 Years - 75 Years | National Cancer Center, Korea | |
| Pembrolizumab in Locally Advanced Sinonasal Carcinoma | NCT05925491 | Sinonasal Undif... | Pembrolizumab | 18 Years - | Istituti Clinici Scientifici Maugeri SpA | |
| Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer | NCT00828308 | Prostate Cancer | Ixabepilone Prostatectomy | 18 Years - | Brown University | |
| PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04506281 | Cholangiocarcin... | neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | NCT02436993 | Breast Carcinom... | Carboplatin Paclitaxel Bevacizumab Trastuzumab Pertuzumab | 18 Years - | University of California, Irvine | |
| Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer | NCT01388647 | HER-2 Positive ... | eribulin carboplatin trastuzumab | 18 Years - | Vector Oncology | |
| AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | NCT05578430 | Resectable Hepa... | Cadonilimab TACE Surgery | 18 Years - 75 Years | Sun Yat-sen University | |
| Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) | NCT02676349 | Pancreatic Carc... | mFolfirinox Chemoradiothera... surgery Adjuvant chemot... | 18 Years - 75 Years | Institut de Cancérologie de Lorraine | |
| Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer | NCT00828308 | Prostate Cancer | Ixabepilone Prostatectomy | 18 Years - | Brown University | |
| RAPIDO vs LCRT vs Upfront Surgery - a Prospective Cohort Study | NCT06212128 | Rectal Cancer | RAPIDO TNT LCRT | 21 Years - 99 Years | Sengkang General Hospital | |
| European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] | NCT06137378 | Squamous Cell C... Hypopharyngeal ... Laryngeal Squam... Laryngeal Squam... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Laryngeal Squam... Laryngectomy; S... Laryngeal Cance... Laryngeal Neopl... | KEYTRUDA® | 18 Years - 70 Years | University of Leipzig | |
| NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | NCT04335669 | Breast Cancer Triple Negative... | epirubicin, cyc... epirubicin, cyc... | 18 Years - 75 Years | Lund University Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
